Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alzamend Neuro Inc
(NQ:
ALZN
)
3.080
-0.310 (-9.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alzamend Neuro Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
May 24, 2023
These biotech stocks with high return potential are poised to provide quick returns for investors who invest over the next year.
Via
InvestorPlace
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
May 11, 2023
These 3 penny stocks have 10X potential over the next twelve months, providing the right risk/reward bet for certain investors.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
April 12, 2023
Via
Benzinga
Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial
October 05, 2022
Via
Benzinga
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 04, 2023
From
Ault Alliance, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine
April 03, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has initiated a Phase 1/2A trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of Alzheimer’s type.
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
March 22, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) announced it had completed the clinical portion of its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer’s.
Via
Benzinga
KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
Via
Business Wire
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
March 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.
Via
Benzinga
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 14, 2023
Via
Benzinga
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
March 22, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 10, 2023
Via
Benzinga
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
March 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 28, 2022
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia
December 28, 2022
Alzamend Neuro Inc (NASDAQ: ALZN) has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.
Via
Benzinga
Alzamend Neuro to Present at Sequire Biotechnology Conference
January 26, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud
December 14, 2022
Eight people connected to Atlas Trading, a Discord-based community, have been named in a complaint filed by the Securities and Exchange Commission (SEC). Co-founders of the forum, podcasters, and...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 02, 2022
We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Friday morning!
Via
InvestorPlace
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
January 04, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 29, 2022
Via
Benzinga
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
December 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
November 22, 2022
Via
ACCESSWIRE
Stocks That Hit 52-Week Lows On Friday
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 16, 2022
Via
Benzinga
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
November 15, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 02, 2022
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday!
Via
InvestorPlace
5.6 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
November 02, 2022
The Nasdaq Composite closed lower by around 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...
Via
Benzinga
WaveDancer And 1 Other Stock Under $2 Insiders Are Aggressively Buying
October 10, 2022
The Dow Jones dropped by more than 600 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
October 31, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.